JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Sanchez G. A. M., Reinhardt A., Ramsey S., Wittkowski H., Hashkes P. J., Berkun Y., ...Daha Fazla

JOURNAL OF CLINICAL INVESTIGATION, cilt.128, sa.7, ss.3041-3052, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 128 Sayı: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1172/jci98814
  • Dergi Adı: JOURNAL OF CLINICAL INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3041-3052
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND. Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease.